Spruce Biosciences
SPRB
43 hedge funds and large institutions have $118M invested in Spruce Biosciences in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 16 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
5% more funds holding
Funds holding: 41 → 43 (+2)
2.14% less ownership
Funds ownership: 86.14% → 84% (-2.1%)
13% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 16
48% less capital invested
Capital invested by funds: $225M → $118M (-$107M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$1.28M |
| 2 |
Renaissance Technologies
New York
|
+$284K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$204K |
| 4 |
Millennium Management
New York
|
+$179K |
| 5 |
Two Sigma Advisers
New York
|
+$161K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
-$8.82M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.96M |
| 4 |
CCM
CAAS Capital Management
New York
|
-$543K |
| 5 |
Morgan Stanley
New York
|
-$391K |
SPRB Hedge Fund Activity: Q3 2021 in Review
43 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q3 2021, worth a combined $118M — down 48% from $225M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new SPRB positions and 4 closed out — a net gain of 2 holders — while 14 added to existing stakes and 16 trimmed.
The largest buyer was Deerfield Management, adding an estimated $1.28M. The largest seller was Sands Capital Management, exiting entirely with an estimated $8.82M sold.
- 43 institutional investors held Spruce Biosciences (SPRB) as of Q3 2021, up from 41 in Q2 2021.
- Funds reported $118M of Spruce Biosciences stock for Q3 2021, down 48% quarter-over-quarter.
- 6 funds opened new Spruce Biosciences positions in Q3 2021 and 4 closed out, a net change of +2 holders.
- The largest Spruce Biosciences buyer in Q3 2021 was Deerfield Management, an estimated $1.28M added.
- The largest Spruce Biosciences seller in Q3 2021 was Sands Capital Management, an estimated $8.82M sold.
Based on aggregated 13F filings for Q3 2021.